DexCom, Inc.

DXCM Stock Report Card

Today's performance

B

Performance

Score: 100/100

A+

DXCM returned 55.29% in the last 12 months. Based on the other stocks in its sector with an average return of -5.77%, its performance is above average giving it a grade of 100 of 100.

Forecast

Score: 76/100

18 analysts offer 12-month price forecasts for DXCM. Together, they have an average target of 70.33, the most optimistic forecast put DXCM at 146 within 12-months and the most pessimistic has DXCM at 28.12.

Technicals

Score: 93/100

A+

DXCM receives a 92 of 100 based on 14 indicators. 12 are bullish, 0 are bearish.

Earnings

Score: 20/100

DXCM has missed earnings 4 times in the last 20 quarters.

Profit

Score: 52/100

Out of the last 20 quarters, DXCM has had 16 profitable quarters and has increased their profits year over year on 5 of them.

Volatility

Score: 54/100

DXCM has had a higher than average amount of volatility over the last 12 months giving it a grade of 53 of 100.

DexCom, Inc. Summary

Nasdaq / DXCM

Healthcare

Medical Devices

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Power up your portfolio

Build a portfolio of the best stocks

Pluto makes it easy to build investing strategies and automate your portfolio

See how

Checkout Similar Companies

DXCM scored highly on our reportcard. Here are some similar companies and how they performed.

AstraZeneca PLC

$AZN Stock Report Card

UNITEDHEALTH GROUP INCORPORATED (Delaware)

$UNH Stock Report Card

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

$GSK Stock Report Card

Humana Inc.

$HUM Stock Report Card

McKesson Corporation

$MCK Stock Report Card

Edwards Lifesciences Corp

$EW Stock Report Card

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

$TAK Stock Report Card

Moderna, Inc. Common Stock

$MRNA Stock Report Card

View all stock report cards

Los Angeles, CA

Pluto is not a broker-dealer, investment adviser or member of FINRA. Securities offered by Alpaca Securities LLC (“Alpaca Securities”). Alpaca Securities is a member of FINRA and the Securities Investor Protection Corporation.

Alpaca Securities, LLC (“Alpaca Securities”) is not responsible for and is not providing the technology and services you receive from us to access and manage your brokerage account with Alpaca Securities. You firmly agree to hold Alpaca and its affiliates, owners, directors, employees, clearing firm and agents harmless for any loss or damage arising from the use of or unavailability of the technology and services that we are providing.

The content on this website is for informational purposes only. Pluto does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing.